Literature DB >> 24528156

Targeted cancer therapies, part 2 #277.

Helen Gharwan, Hunter Groninger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24528156      PMCID： PMC3952658          DOI： 10.1089/jpm.2014.9444

Source DB:  PubMed          Journal:  J Palliat Med        ISSN： 1557-7740            Impact factor:   2.947


× No keyword cloud information.
  9 in total

Review 1.  Improving the efficacy of antibody-based cancer therapies.

Authors:  P Carter
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

2.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

Review 3.  Development trends for human monoclonal antibody therapeutics.

Authors:  Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal:  Nat Rev Drug Discov       Date:  2010-09-03       Impact factor: 84.694

Review 4.  Adverse effects of the humanized antibodies used as cancer therapeutics.

Authors:  Jean Klastersky
Journal:  Curr Opin Oncol       Date:  2006-07       Impact factor: 3.645

5.  Therapeutic antibodies and derivatives: from the bench to the clinic.

Authors:  A Beck; T Wurch; N Corvaïa
Journal:  Curr Pharm Biotechnol       Date:  2008-12       Impact factor: 2.837

Review 6.  Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review.

Authors:  J M Baas; L L Krens; H-J Guchelaar; J Ouwerkerk; F A de Jong; A P M Lavrijsen; H Gelderblom
Journal:  Cancer Treat Rev       Date:  2011-11-17       Impact factor: 12.111

Review 7.  Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management.

Authors:  Alessandra Vultaggio; Enrico Maggi; Andrea Matucci
Journal:  Curr Opin Allergy Clin Immunol       Date:  2011-06

Review 8.  Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review.

Authors:  Marek Svoboda; Alexandr Poprach; Svatopluk Dobes; Igor Kiss; Rostislav Vyzula
Journal:  Cardiovasc Toxicol       Date:  2012-09       Impact factor: 3.231

Review 9.  Cutaneous adverse reactions to therapeutic monoclonal antibodies for cancer.

Authors:  Patricia L Myskowski; Allan C Halpern
Journal:  Curr Allergy Asthma Rep       Date:  2008-03       Impact factor: 4.806
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.